MADRIGAL PHARMACEUTICALS, INC. Earnings Per Share (Diluted)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Earnings Per Share (Diluted) of -$1.99 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.99.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$3.25.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$2.03.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$4.01.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2022 was -$17.23.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2021 was -$14.63.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2020 was -$13.09.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2011 was -$1.00.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.99 10-Q · filed 2026-07-30 | -$5.24 10-Q · filed 2026-07-30 | -$7.27 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$11.26 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||||
| 2026-03-31 | -$3.25 10-Q · filed 2026-05-06 | -$5.29 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$9.28 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$10.80 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||||
| 2025-12-31 | -$2.03 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$6.03 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$7.54 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$10.15 10-Q · filed 2026-07-30 | -$12.85 10-K · filed 2026-02-19 | |||
| 2025-09-30 | -$4.01 10-Q · filed 2026-07-30 | -$5.08 10-Q · filed 2025-11-04 | -$5.52 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$8.12 10-Q · filed 2026-07-30 | -$10.32 10-Q · filed 2025-11-04 | -$8.94 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-06-30 | -$1.50 10-Q · filed 2026-07-30 | -$1.90 10-Q · filed 2025-08-05 | -$4.10 10-Q · filed 2026-07-30 | -$5.22 10-Q · filed 2025-08-05 | -$5.21 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$9.20 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-03-31 | -$2.61 10-Q · filed 2026-05-06 | -$3.32 10-Q · filed 2025-05-01 | -$3.66 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$7.62 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$13.54 derived: net income ÷ weighted average shares · filed 2026-07-30 | |||
| 2024-12-31 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$5.03 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$10.90 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$17.31 10-Q · filed 2026-07-30 | -$21.90 10-K · filed 2025-02-26 | |||
| 2024-09-30 | -$4.92 10-Q · filed 2025-11-04 | -$12.00 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$19.31 10-Q · filed 2025-11-04 | -$25.02 derived: net income ÷ weighted average shares · filed 2025-11-04 | ||||
| 2024-06-30 | -$7.10 10-Q · filed 2025-08-05 | -$14.47 10-Q · filed 2025-08-05 | -$20.19 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$25.64 derived: net income ÷ weighted average shares · filed 2025-11-04 | ||||
| 2024-03-31 | -$7.38 10-Q · filed 2025-05-01 | -$13.06 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$18.47 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$23.21 derived: net income ÷ weighted average shares · filed 2025-11-04 | ||||
| 2023-12-31 | -$5.68 10-K · filed 2024-02-28 | -$11.03 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$15.74 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$17.33 10-Q · filed 2026-07-30 | -$19.99 10-K · filed 2024-02-28 | |||
| 2023-09-30 | -$5.34 10-Q · filed 2024-10-31 | -$10.03 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$14.27 10-Q · filed 2024-10-31 | -$19.24 derived: net income ÷ weighted average shares · filed 2024-10-31 | ||||
| 2023-06-30 | -$4.69 10-Q · filed 2024-08-07 | -$8.91 10-Q · filed 2024-08-07 | -$13.88 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$18.62 derived: net income ÷ weighted average shares · filed 2024-10-31 | ||||
| 2023-03-31 | -$4.23 10-Q · filed 2024-05-07 | -$9.19 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$13.94 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$18.08 derived: net income ÷ weighted average shares · filed 2024-10-31 | ||||
| 2022-12-31 | -$4.98 10-K · filed 2024-02-28 | -$9.73 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$13.87 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$17.23 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | -$4.75 10-K · filed 2024-02-28 | -$8.88 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$12.25 10-Q · filed 2023-11-06 | -$16.03 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2022-06-30 | -$4.14 10-K · filed 2024-02-28 | -$7.50 10-Q · filed 2023-08-08 | -$11.28 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$15.07 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2022-03-31 | -$3.36 10-K · filed 2024-02-28 | -$7.14 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$10.93 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$14.65 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2021-12-31 | -$3.78 10-K/A · filed 2023-03-03 | -$7.57 derived: net income ÷ weighted average shares · filed 2023-03-03 | -$11.29 derived: net income ÷ weighted average shares · filed 2023-03-03 | -$14.63 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | -$3.79 10-K/A · filed 2023-03-03 | -$7.51 derived: net income ÷ weighted average shares · filed 2023-03-03 | -$10.84 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$3.72 10-K/A · filed 2023-03-03 | -$7.05 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$3.32 10-K/A · filed 2023-03-03 | |||||||
| 2020-12-31 | -$13.09 10-K/A · filed 2023-03-03 | |||||||
| 2011-12-31 | -$1.00 10-K · filed 2012-02-22 | |||||||
| 2010-12-31 | -$0.93 10-K · filed 2012-02-22 | |||||||
| 2009-12-31 | $2.32 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |